New Delhi, Sept. 28
Ranbaxy Laboratories Ltd (RLL) on Wednesday announced that the company's wholly-owned subsidiary, Ranbaxy Malaysia Sdn Bhd. (RMSB), has launched the first generic Atorvastatin under the brand name, `Storvas', in Malaysia. The product will be made available through all major general practitioners, pharmacies and hospitals in Malaysia. Storvas will be sold in dosage forms of 10 mg, 20 mg and 40 mg.
Commenting on the launch, Mr T. Jeyabalan, Managing Director, RMSB, said, "Ranbaxy is proud to be the first company to launch the generic alternatives of Atorvastatin and Oseltamivir in Malaysia. It is our constant endeavour to offer affordable and safe generics of high quality to the patients in Malaysia and provide support to the government's healthcare plan."